Guanylyl cyclase C in colorectal cancer: Susceptibility gene and potential therapeutic target

Future Oncology

Volumn 5, Issue 4, 2009, Pages 509-522

  Lin, Jieru E ^a   Li, Peng ^a   Pitari, Giovanni M ^a   Schulz, Stephanie ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

AKT; Cell cycle; Colorectal cancer; Genomic instability; Guanylin; Guanylyl cyclase C; Hormone insufficiency; Hormone replacement therapy; Lineage specific tumorigenesis; Metabolism; Proliferation; Uroguanylin

Indexed keywords

GUANYLATE CYCLASE; GUANYLATE CYCLASE C; GUANYLIN; HORMONE; INSULIN; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; UROGUANYLIN; ENTEROTOXIN RECEPTOR; RECEPTOR;

APOPTOSIS; CANCER CELL; CANCER GENETICS; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL CYCLE REGULATION; COLON CARCINOGENESIS; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; FATTY ACID OXIDATION; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HORMONE SUBSTITUTION; HUMAN; INHERITANCE; MALIGNANT TRANSFORMATION; METASTASIS; MOLECULAR EVOLUTION; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; UPREGULATION; ANIMAL; CELL TRANSFORMATION; COLORECTAL TUMOR; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GUANYLATE CYCLASE; HUMANS; RECEPTORS, PEPTIDE;

EID: 67651227644     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.14     Document Type: Review

References (141)

1. Boyle P, Levin B: World cancer report 2008. In: International agency for research on cancer. IARC Nonserial Publication, Geneva, Switzerland 2008).
2. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
3. McCracken M, Olsen M, Chen MS Jr et al.: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin. 57, 190-205 (2007).
4. Cubas R, Li M, Chen C, Yao Q: Colorectal cancer: New advances in immunotherapy. Cancer Biol. Ther. 6(1), 11-17 (2007).
5. Sanoff HK, Sargent DJ, Campbell ME et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J. Clin. Oncol. 26, 5721-5727 (2008).
6. Falcone A, Ricci S, Brunetti I et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25, 1670-1676 (2007).
7. de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C: Targeted agents for adjuvant therapy of colon cancer. Semin. Oncol. 33(Suppl. 11), 42-45 (2006).
8. Marshall, J: Optimum use of biologics and role of maintenance therapy in colon cancer. Semin. Oncol. 33(Suppl. 11), 33-35 (2006).
9. Thomson WH, Foy CJ, Longman RJ: The nature of local recurrence after colorectal cancer resection. Colorectal Dis. 10, 69-74 (2008).
10. Zak Y, Moore HG, Ghosh BC: Patterns of recurrence of colorectal cancer. J. Surg. Oncol. 97, 1-2 (2008).
11. Fodde R, Smits R, Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55-67 (2001).
12. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
13. Garraway LA, Sellers WR: Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 6, 593-602 (2006).
14. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100, 57-70 (2000).
15. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004).
16. van de Wetering M, Sancho E, Verweij C et al.: The β-catenin/ TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250 (2002).
17. Sansom OJ, Reed KR, Hayes AJ et al.: Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 18, 1385-1390 (2004).
18. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430 (2006).
19. + myeloid cells that promote invasion. Nat. Genet. 39, 467-475 (2007).
20. Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8, 387-398 (2008).
21. 2 availability on human cancer. Nat. Rev. Cancer 8, 967-975 (2008).
22. Bode AM, Dong Z: Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4, 793-805 (2004).
23. Bonner WM, Redon CE, Dickey JS et al.: γH2AX and cancer. Nat. Rev. Cancer 8, 957-967 (2008).
24. Green DR, Chipuk JE: p53 and metabolism: Inside the TIGAR. Cell 126, 30-32 (2006).
25. Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence? Nat. Rev. Cancer 2, 777-785 (2002).
26. Clevers, H: Wnt/β-catenin signaling in development and disease. Cell 127, 469-480 (2006).
27. Hahn WC, Weinberg RA: Rules for making human tumor cells. N. Engl. J. Med. 347, 1593-1603 (2002).
28. Kho AT, Zhao Q, Cai Z et al.: Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 18, 629-640 (2004).
29. Barker N, van de Wetering M, Clevers H: The intestinal stem cell. Genes Dev. 22, 1856-1864 (2008).
30. Humphries A, Wright NA: Colonic crypt organization and tumorigenesis. Nat. Rev. Cancer 8, 415-424 (2008).
31. van den Brink GR, Offerhaus GJ: The morphogenetic code and colon cancer development. Cancer Cell 11, 109-117 (2007).
32. Kazanskaya O, Glinka A, del Barco Barrantes I et al.: R-Spondin2 is a secreted activator of Wnt/β-catenin signaling and is required for Xenopus myogenesis. Dev. Cell 7, 525-534 (2004).
33. Xu Q, Wang Y, Dabdoub A et al.: Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 116, 883-895 (2004).
34. Peifer M, Sweeton D, Casey M, Wieschaus E: Wingless signal and Zeste-white 3 kinase trigger opposing changes in the intracellular distribution of Armadillo. Development 120, 369-380 (1994).
35. Peters JM, McKay RM, McKay JP, Graff JM: Casein kinase I transduces Wnt signals. Nature 401, 345-350 (1999).
36. Sakanaka C, Leong P, Xu L, Harrison SD, Williams LT: Casein kinase iepsilon in the wnt pathway: regulation of β-catenin function. Proc. Natl Acad. Sci. USA 96, 12548-12552 (1999).
37. Amit S, Hatzubai A, Birman Y et al.: Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066-1076 (2002).
38. Liu C, Li Y, Semenov M et al.: Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847 (2002).
39. Yanagawa S, Matsuda Y, Lee JS et al.: Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J. 21, 1733-1742 (2002).
40. Salomon D, Sacco PA, Roy SG et al.: Regulation of β-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J. Cell Biol. 139, 1325-1335 (1997).
41. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R: β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804 (1997).
42. Behrens J, von Kries JP, Kuhl M et al.: Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382, 638-642 (1996).
43. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R: Nuclear localization of β-catenin by interaction with transcription factor LEF-1. Mech. Dev. 59, 3-10 (1996).
44. Molenaar M, van de Wetering M, Oosterwegel M et al.: XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 86, 391-399 (1996).
45. He TC, Sparks AB, Rago C et al.: Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998).
46. Shtutman M, Zhurinsky J, Simcha I et al.: The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl Acad. Sci. USA 96, 5522-5527 (1999).
47. Tetsu O, McCormick F: B-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426 (1999).
48. Davidson G, Wu W, Shen J et al.: Casein kinase 1 γ couples Wnt receptor activation to cytoplasmic signal transduction. Nature 438, 867-872 (2005).
49. Zeng X, Tamai K, Doble B et al.: A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873-877 (2005).
50. Yamamoto H, Komekado H, Kikuchi A: Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of β-catenin. Dev. Cell 11, 213-223 (2006).
51. Bilic J, Huang YL, Davidson G et al.: Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 316, 1619-1622 (2007).
52. Ashton-Rickardt PG, Dunlop MG, Nakamura Y et al.: High frequency of APC loss in sporadic colorectal carcinoma due to breaks clustered in 5q21-22. Oncogene 4, 1169-1174 (1989).
53. Groden J, Thliveris A, Samowitz W et al.: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589-600 (1991).
54. Powell SM, Zilz N, Beazer-Barclay Y et al.: APC mutations occur early during colorectal tumorigenesis. Nature 359, 235-237 (1992).
55. Su LK, Kinzler KW, Vogelstein B et al.: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670 (1992).
56. Kinzler KW, Nilbert MC, Su LK et al.: Identification of FAP locus genes from chromosome 5q21. Science 253, 661-665 (1991).
57. Forte LR Jr: Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol. Ther. 104, 137-162 (2004).
58. Lucas KA, Pitari GM, Kazerounian S et al.: Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-414 (2000).
59. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM: Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 171, 1847-1858 (2007).
60. Li P, Schulz S, Bombonati A et al.: Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133, 599-607 (2007).
61. Steinbrecher KA, Wowk SA, Rudolph JA, Witte DP, Cohen MB: Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am. J. Pathol. 161, 2169-2178 (2002).
62. Birkenkamp-Demtroder K, Lotte Christensen L, Harder Olesen S et al.: Gene expression in colorectal cancer. Cancer Res. 62, 4352-4363 (2002).
63. Cohen MB, Hawkins JA, Witte DP: Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab. Invest. 78, 101-108 (1998).
64. Notterman DA, Alon U, Sierk AJ, Levine AJ: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61, 3124-3130 (2001).
65. Li P, Lin JE, Snook AE et al.: Colorectal cancer as a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clin. Transl. Sci. 1, 163-167 (2008).
66. Li P, Lin JE, Snook AE et al.: Colorectal cancer is a paracrine deficiency syndrome which can be prevented and treated by oral hormone replacement therapy Curr. Mol. Pharmacol. (2008) (In press).
67. Pitari GM, Baksh RI, Harris DM et al.: Interruption of homologous desensitization in cyclic guanosine 3′,5′-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 65, 11129-11135 (2005).
68. Pitari GM, Di Guglielmo, Park J, Schulz S, Waldman SA: Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl Acad. Sci. USA 98, 7846-7851 (2001).
69. Pitari GM, Zingman LV, Hodgson DM et al.: Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl Acad. Sci. USA 100, 2695-2699 (2003).
70. Pitari GM, Li P, Lin JE et al.: The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol. Ther. 82, 441-447 (2007).
71. Shailubhai K, Yu HH, Karunanandaa K et al.: Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 60, 5151-5157 (2000).
72. Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY: Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294, 2155-2158 (2001).
73. Chung S, Dzeja PP, Faustino RS et al.: Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1), S60-S67 (2007).
74. Lonergan T, Brenner C, Bavister B: Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. J. Cell Physiol. 208, 149-153 (2006).
75. Assaily W, Benchimol S: Differential utilization of two ATP-generating pathways is regulated by p53. Cancer Cell 10, 4-6 (2006).
76. Altenberg B, Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84, 1014-1020 (2004).
77. Kondoh H, Lleonart ME, Nakashima Y et al.: A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid. Redox Signal. 9, 293-299 (2007).
78. Xu RH, Pelicano H, Zhou Y et al.: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65, 613-621 (2005).
79. Balaban RS, Nemoto S, Finkel T: Mitochondria, oxidants, and aging. Cell 120, 483-495 (2005).
80. Chan DC: Mitochondria: dynamic organelles in disease, aging, and development. Cell 125, 1241-1252 (2006).
81. Cho YM, Kwon S, Pak YK et al.: Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. Biochem. Biophys. Res. Commun. 348, 1472-1478 (2006).
82. Nesti C, Pasquali L, Vaglini F, Siciliano G, Murri L: The role of mitochondria in stem cell biology. Biosci Rep 27, 165-171 (2007).
83. Gassler N, Newrzella D, Bohm C et al.: Molecular characterization of non-absorptive and absorptive enterocytes in human small intestine. Gut 55, 1084-1089 (2006).
84. Jeynes BJ, Altmann GG: A region of mitochondrial division in the epithelium of the small intestine of the rat. Anat. Rec. 182, 289-296 (1975).
85. Bui T, Thompson CB: Cancer's sweet tooth. Cancer Cell 9, 419-420 (2006).
86. Cuezva JM, Krajewska M, de Heredia ML et al.: The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 62, 6674-6681 (2002).
87. Gatenby RA, Gawlinski ET: The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 63, 3847-3854 (2003).
88. Kroemer G: Mitochondria in cancer. Oncogene 25, 4630-4632 (2006).
89. Baron A, Migita T, Tang D, Loda M: Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell Biochem. 91, 47-53 (2004).
90. Calvo MN, Bartrons R, Castano E et al.: PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett. 580, 3308-3314 (2006).
91. Garber K: Energy boost: the Warburg effect returns in a new theory of cancer. J. Natl Cancer Inst. 96, 1805-1806 (2004).
92. Lu H, Forbes RA, Verma A: Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277, 23111-23115 (2002).
93. Pelicano H, Xu RH, Du M et al.: Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell Biol. 175, 913-923 (2006).
94. Rider MH, Bertrand L, Vertommen D et al.: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J. 381, 561-579 (2004).
95. Unwin RD, Craven RA, Harnden P et al.: Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3, 1620-1632 (2003).
96. Li X, Monks B, Ge Q, Birnbaum MJ: Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α transcription coactivator. Nature 447, 1012-1016 (2007).
97. +/- compound mutant mice. Nat. Genet. 35, 323-330 (2003).
98. Spruck CH, Won KA, Reed SI: Deregulated cyclin E induces chromosome instability. Nature 401, 297-300 (1999).
99. Bristow RG, Hill RP: Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180-192 (2008).
100. Lombard DB, Chua KF, Mostoslavsky R et al.: Drepair NA, genome stability, and aging. Cell 120, 497-512 (2005).
101. Bos JL, Fearon ER, Hamilton SR et al.: Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297 (1987).
102. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
103. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327, 298-303 (1987).
104. Benito M, Diaz-Rubio E: Molecular biology in colorectal cancer. Clin. Transl. Oncol. 8, 391-398 (2006).
105. Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14, 3102-3114 (2000).
106. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
107. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
108. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274 (2007).
109. Lim KH, Ancrile BB, Kashatus DF, Counter CM: Tumor maintenance is mediated by eNOS. Nature 452, 646-649 (2008).
110. He XC, Zhang J, Tong WG et al.: BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nat. Genet. 36, 1117-1121 (2004).
111. Brazil DP, Park J, Hemmings BA: PKB binding proteins. Getting in on the Akt. Cell 111, 293-303 (2002).
112. Lei Q, Jiao J, Xin L et al.: NKX3.1 stabilizes p53, inhibits activation KT, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9, 367-378 (2006).
113. Crowell JA, Steele VE, Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol. Cancer Ther. 6, 2139-2148 (2007).
114. Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262 (2003).
115. Frame S, Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 359, 1-16 (2001).
116. Minella AC, Clurman BE: Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 4, 1356-1359 (2005).
117. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr: The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33 (2005).
118. Welcker M, Singer J, Loeb KR et al.: Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12, 381-392 (2003).
119. Yeh E, Cunningham M, Arnold H et al.: A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6, 308-318 (2004).
120. Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829-1834 (2003).
121. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657 (2002).
122. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
123. Edinger AL, Thompson CB: Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276-2288 (2002).
124. Plas DR, Thompson CB: Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435-7442 (2005).
125. Mamane Y, Petroulakis E, Rong L et al.: eIF4E - from translation to transformation. Oncogene 23, 3172-3179 (2004).
126. Soussi T, Wiman KG: Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12, 303-312 (2007).
127. Puc J, Keniry M, Li HS et al.: Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7, 193-204 (2005).
128. King FW, Skeen J, Hay N, Shtivelman E: Inhibition of Chk1 by activated PKB/Akt. Cell Cycle 3, 634-637 (2004).
129. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM: The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J. Biol. Chem. 277, 33895-33900 (2002).
130. Sundqvist A, MT Bengoechea-Alonso, Ye X et al.: Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 1, 379-391 (2005).
131. Hammerman PS, Fox CJ, Thompson CB: Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends. Biochem. Sci. 29, 586-592 (2004).
132. Gordan JD, Simon MC: Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 17, 71-77 (2007).
133. Semenza GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
134. Majumder PK, Sellers WR: Akt-regulated pathways in prostate cancer. Oncogene 24, 7465-7474 (2005).
135. Accili D, Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426 (2004).
136. Van Remmen H, Ikeno Y, Hamilton M et al.: Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol, Genomics 16, 29-37 (2003).
137. Zhao Y, Oberley TD, Chaiswing L et al.: Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model. Oncogene 21, 3836-3846 (2002).
138. +/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc. Natl Acad. Sci. USA 98, 2278-2283 (2001).
139. Birbe R, Palazzo JP, Walters R et al.: Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 36, 170-179 (2005).
140. Schulz S, Hyslop T, Haaf J et al.: A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 12, 4545-4552 (2006).
141. Eaves CJ: Cancer stem cells: here, there, everywhere? Nature 456, 581-582 (2008).